The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001362381p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
2/11/2026
Date registered
Help: Date registered
16/11/2026
Date last updated
Help: Date last updated
16/11/2026
Date data sharing statement initially provided
Help: Data sharing statement date
16/11/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Effects of a digital unsupervised Pilates program (“My Joint Pilates”) on physical function in people with hip osteoarthritis: randomised controlled trial (The PILLAR HIP Trial)
Scientific title
Effects of a 12-week digital unsupervIsed PILates program (“My Joint PiLates”), compared with online education, on self-reported physical function in people with hip osteoArthRitis: randomised controlledtrial (The PILLAR HIP Trial)
Additional trial identifiers [1] 318794 0
National Health and Medical Research Council (NHMRC) Investigator Grant: 2033150
Universal Trial Number (UTN)
U1111-1349-1203
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Hip osteoarthritis 344041 0
Condition category
Condition code
Musculoskeletal 340173 340173 0 0
Osteoarthritis
Physical Medicine / Rehabilitation 340174 340174 0 0
Other physical medicine / rehabilitation

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Intervention brief name: Digital unsupervised “My Joint Pilates” program. Materials: Participants in the intervention group will have access to a bespoke website (“My Joint Pilates”) designed specifically for this study, developed in accordance with the Health on the Net Foundation Code of Conduct and refined with input from people with hip/knee osteoarthritis (OA). The website contains:
i) a self-directed 12-week progressive Pilates exercise;
ii) introductory information about Pilates (what Pilates is, key Pilates principles and potential health benefits), including a link to a professional directory of Pilates instructors;
iii) written educational information about living with OA, OA treatments and the benefits of exercise, complemented by video interviews with OA experts;
iv) information about exercise adherence and the free “My Exercise Messages” app. The homepage includes a video tutorial explaining how to use the website.

The Pilates exercise was co-designed by OA researchers, physiotherapists, Pilates experts and people with hip/knee OA. It comprises a series of pre-recorded videos (approximately 30 minutes each) filmed in a class format, led by an instructor with two participants, each demonstrating a different difficulty level of the same movement and participants are guided to select the level that suits them and to progress or regress as appropriate. Each video includes Pilates exercises performed in standing, sitting and lying positions. The program starts with simple Pilates movements, with new movements progressively added across the 12 weeks, and aims to enhance general mobility and strength with a focus on hip and knee function and stability. Equipment includes a mat and a chair; a resistance band is optional for some exercises, which can also be performed without one. Movements were modified to ensure suitability for people with hip and knee OA and little prior Pilates experience. The exercise section also explains how to prepare for the program and how to manage exercise-related pain.

Who delivers: The program is led on video by a physiotherapist-qualified Pilates instructor with over 25 years of exercise teaching experience. No live supervision is provided.

Mode of delivery: Online via the bespoke study website, accessed individually on the participant’s own device; unsupervised.

Dose/schedule: Participants are asked to complete the Pilates program three times per week for 12 weeks (approximately 30 minutes per session), at a time of their choosing. Participants are asked to access the website and start the program within 3 days of receiving their access email, and can view the website as often as they wish.

Location: Participant’s home, anywhere in Australia.

Adherence support and monitoring: Participants are encouraged to download and use the free “My Exercise Messages” app (App Store and Google Play) for the full 12 weeks. After entering their name, the program duration (12 weeks) and prescribed frequency (3 days/week), they receive a weekly notification to record the number of Pilates sessions completed in the past week. If fewer than three sessions are reported, they select a reason from a list of common exercise barriers and receive a tailored behaviour change message; they also receive two motivational notifications each week. Adherence will be measured by self-reported number of Pilates sessions (reported fortnightly over the 12 weeks), use of the app, and the Exercise Adherence Rating Scale at 13 weeks.
Intervention code [1] 335690 0
Treatment: Other
Intervention code [2] 335691 0
Rehabilitation
Description of the comparator or control
Online education: Participants in the control group will have access to a separate bespoke website containing only the education section of the “My Joint Pilates” website (written information about OA, OA treatments and exercise, plus OA expert video interviews). It does not contain information about Pilates, the Pilates exercise program, or the adherence app. Participants are asked to access the website on their own device within 3 days, read the information and implement recommendations as they see fit, and may view it as often as they wish. The educational information was designed specifically for this study.
Control group
Active

Outcomes
Primary outcome [1] 347315 0
Self-reported physical function
Timepoint [1] 347315 0
Baseline, 13 weeks after randomisation (primary timepoint)
Secondary outcome [1] 470231 0
Overall average hip pain during walking in the past week
Timepoint [1] 470231 0
Baseline, 13 weeks after randomisation
Secondary outcome [2] 470232 0
Function in sport and recreation
Timepoint [2] 470232 0
Baseline, 13 weeks after randomisation
Secondary outcome [3] 470233 0
Hip-related Quality of Life
Timepoint [3] 470233 0
Baseline, 13 weeks after randomisation
Secondary outcome [4] 470234 0
Global rating of overall change in hip condition
Timepoint [4] 470234 0
13 weeks after randomisation
Secondary outcome [5] 470235 0
Fear of movement
Timepoint [5] 470235 0
Baseline, 13 weeks after randomisation
Secondary outcome [6] 470236 0
Pain self-efficacy
Timepoint [6] 470236 0
Baseline, 13 weeks after randomisation
Secondary outcome [7] 470237 0
Balance confidence
Timepoint [7] 470237 0
Baseline, 13 weeks after randomisation

Eligibility
Key inclusion criteria
i) National Institute for Health and Care Excellence clinical criteria for hip osteoarthritis:
i. age greater than or equal to 45 years;
ii. activity-related hip joint pain;
iii. no morning hip stiffness or morning hip stiffness greater than or equal to 30 minutes;
ii) live in Australia;
iii) report hip pain for greater than or equal to 3 months;
iv) report hip pain on most days in the past month;
v) report at least mild physical dysfunction (score >20 out of 68 on Western Ontario McMaster Universities (WOMAC) physical function subscale);
vi) have a home internet connection and a computer/tablet device that enables access to the internet
vii) have a smartphone with an operating system that supports downloading and using the study app
viii) able to participate fully in the intervention and assessment procedures and provide informed consent (e.g. not planning a holiday in the coming 13 weeks).
Minimum age
45 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
i) previous hip joint replacement on affected side;
ii) recent hip surgery (past 6 months) on both sides;
iii) on waiting list for/planning hip surgery in next 3 months;
iv) having an appointment with an orthopaedic surgeon for hip problems in the next 3 months
v) participated in regular exercise (home-based leg strengthening exercises, swimming/water exercises, cycling or attending a gym or group exercise classes such as Pilates, Yoga, Tai Chi) at least once per week over the last 2 months
vi) intending to/planning to commence regular exercise (home-based leg strengthening exercises, swimming/water exercises, cycling or attending a gym or group exercise classes such as Pilates, Yoga, Tai Chi) (at least once per week) in the next 3 months;
vii) unable to walk unaided (without use of a frame or walking stick);
viii) self-reported (at screening) inflammatory arthritis (e.g. rheumatoid arthritis);
ix) history of a fall (past 12 months) and no general practitioner (GP) clearance to participate;
x) house-bound due to immobility and unable to leave the house in the last month without assistance from another person and do not receive medical clearance from a GP (general practitioner) to participate in an unsupervised home exercise program;
xi) have a health condition(s) listed on the Exercise and Sports Science Australia stage 1 pre-exercise screening questionnaire that might compromise exercise safety [32] and do not receive medical clearance from a GP to participate;
xii) unable to commit to study requirements;
xiii) previously participated in a CHESM clinical trial in the prior four years, or is currently participating in another research study at CHESM or elsewhere.
xiv) unable to read or speak English.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
The randomization schedule will be prepared by the biostatistician. The schedule will be stored on a password-protected website (REDCap) maintained by a researcher not involved in either participant recruitment or administration of primary/secondary outcome measures. Group allocation will be revealed by this same researcher after baseline primary/secondary outcomes have been completed.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Randomisation will occur according to a 1: 1 allocation. The randomisation schedule will be prepared by the biostatistician, and will be prepared using permuted blocks of varying sizes.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
Sample size calculation:
The sample size is based on detecting a conservative standardised effect size of 0.40 (small to moderate between-group difference; Cohen, 2013) for the primary outcome of WOMAC physical function, as digital unsupervised exercise may have smaller effects than the effect size of 0.52 for physical function observed with land-based supervised exercise for hip OA (Hall et al., 2026). To achieve 80% power with a two-sided 5% significance level, assuming equal between-participant standard deviations of 1 for both groups and a correlation between pre- and post-measurements of 0.44, and accounting for 15% loss to follow-up, we require 96 participants per arm, for a total of 192 participants.

Statistical analysis plan:
A biostatistician blinded to group allocation will develop a detailed statistical analysis plan, which will be finalised before database lock and unblinding. Analyses comparing the two groups will be performed using all available data from all participants as randomised. Should missing data for the primary outcome exceed 5%, multiple imputation will be used, with the primary analysis using multiply imputed data and a sensitivity analysis using complete cases. Demographic and baseline characteristics will be summarised descriptively and inspected for baseline comparability. The primary outcome (change in WOMAC physical function from baseline to 13 weeks) will be compared between groups using linear regression adjusted for the baseline value, with the between-group difference in mean change reported with a two-sided 95% confidence interval and p-value. Continuous secondary outcomes will be analysed similarly. Model assumptions will be assessed using standard diagnostic plots. Binary secondary outcomes will be compared using log-binomial regression adjusted for the baseline outcome where available, reported as risk ratios and risk differences; should these models fail to converge, logistic regression adjusted for the baseline outcome will be used, with results still reported as risk ratios and risk differences. A supplementary analysis will estimate complier average causal effects on the primary outcome assuming “acceptable” adherence (an average of two or more Pilates sessions per week), using an instrumental variables approach (two-stage least squares, with randomisation as the instrument), reported with 95% confidence intervals and p-values. No interim analyses will be performed.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT,NSW,NT,QLD,SA,TAS,WA,VIC

Funding & Sponsors
Funding source category [1] 323362 0
Government body
Name [1] 323362 0
National Health and Medical Research Council (NHMRC) — Investigator Grant #2033150
Country [1] 323362 0
Australia
Primary sponsor type
University
Name
The University of Melbourne
Address
Country
Australia
Secondary sponsor category [1] 326332 0
None
Name [1] 326332 0
Address [1] 326332 0
Country [1] 326332 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 321753 0
University of Melbourne Human Research Ethics Committee
Ethics committee address [1] 321753 0
Ethics committee country [1] 321753 0
Australia
Date submitted for ethics approval [1] 321753 0
30/10/2026
Approval date [1] 321753 0
Ethics approval number [1] 321753 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 154722 0
Dr Shiyi Julia Zhu
Address 154722 0
Centre for Health, Exercise and Sports Medicine Department of Physiotherapy Level 7, Alan Gilbert Building The University of Melbourne, Carlton, Victoria 3010 Australia
Country 154722 0
Australia
Phone 154722 0
+61 3 8344 9531
Fax 154722 0
Email 154722 0
Contact person for public queries
Name 154723 0
Ben Metcalf
Address 154723 0
Centre for Health, Exercise and Sports Medicine Department of Physiotherapy Level 7, Alan Gilbert Building The University of Melbourne, Carlton, Victoria 3010 Australia
Country 154723 0
Australia
Phone 154723 0
+61 3 83448127
Fax 154723 0
Email 154723 0
Contact person for scientific queries
Name 154724 0
Dr Shiyi Julia Zhu
Address 154724 0
Centre for Health, Exercise and Sports Medicine Department of Physiotherapy Level 7, Alan Gilbert Building The University of Melbourne, Carlton, Victoria 3010 Australia
Country 154724 0
Australia
Phone 154724 0
+61 3 8344 9531
Fax 154724 0
Email 154724 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.